Literature DB >> 33310084

Novel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis.

Heather J Galipeau1, Alberto Caminero1, Williams Turpin2, Miriam Bermudez-Brito1, Alba Santiago1, Josie Libertucci1, Marco Constante1, Juan Antonio Raygoza Garay2, Gaston Rueda1, Sarah Armstrong1, Alex Clarizio1, Michelle I Smith3, Michael G Surette1, Premysl Bercik1, Kenneth Croitoru4, Elena F Verdu5.   

Abstract

BACKGROUND & AIMS: Altered gut microbiota composition and function have been associated with inflammatory bowel diseases, including ulcerative colitis (UC), but the causality and mechanisms remain unknown.
METHODS: We applied 16S ribosomal RNA gene sequencing, shotgun metagenomic sequencing, in vitro functional assays, and gnotobiotic colonizations to define the microbial composition and function in fecal samples obtained from a cohort of healthy individuals at risk for inflammatory bowel diseases (pre-UC) who later developed UC (post-UC) and matched healthy control individuals (HCs).
RESULTS: Microbiota composition of post-UC samples was different from HC and pre-UC samples; however, functional analysis showed increased fecal proteolytic and elastase activity before UC onset. Metagenomics identified more than 22,000 gene families that were significantly different between HC, pre-UC, and post-UC samples. Of these, 237 related to proteases and peptidases, suggesting a bacterial component to the pre-UC proteolytic signature. Elastase activity inversely correlated with the relative abundance of Adlercreutzia and other potentially beneficial taxa and directly correlated with known proteolytic taxa, such as Bacteroides vulgatus. High elastase activity was confirmed in Bacteroides isolates from fecal samples. The bacterial contribution and functional significance of the proteolytic signature were investigated in germ-free adult mice and in dams colonized with HC, pre-UC, or post-UC microbiota. Mice colonized with or born from pre-UC-colonized dams developed higher fecal proteolytic activity and an inflammatory immune tone compared with HC-colonized mice.
CONCLUSIONS: We have identified increased fecal proteolytic activity that precedes the clinical diagnosis of UC and associates with gut microbiota changes. This proteolytic signature may constitute a noninvasive biomarker of inflammation to monitor at-risk populations that can be targeted therapeutically with antiproteases.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Microbiome; Proteolytic Activity; Ulcerative Colitis

Mesh:

Substances:

Year:  2020        PMID: 33310084     DOI: 10.1053/j.gastro.2020.12.004

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

Review 1.  Recipient factors in faecal microbiota transplantation: one stool does not fit all.

Authors:  Camille Danne; Nathalie Rolhion; Harry Sokol
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-04-27       Impact factor: 46.802

2.  Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea.

Authors:  Dale A Fritsch; Matthew I Jackson; Susan M Wernimont; Geoffrey K Feld; Jennifer M MacLeay; John J Brejda; Chun-Yen Cochrane; Kathy L Gross
Journal:  BMC Vet Res       Date:  2022-06-24       Impact factor: 2.792

Review 3.  Multiomics to elucidate inflammatory bowel disease risk factors and pathways.

Authors:  Manasi Agrawal; Kristine H Allin; Francesca Petralia; Jean-Frederic Colombel; Tine Jess
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-03-17       Impact factor: 73.082

4.  Knockdown of long non-coding RNA NEAT1 relieves inflammation of ulcerative colitis by regulating the miR-603/FGF9 pathway.

Authors:  Fengdong Li; Hui Liu; Jinjin Fu; Li Fan; Shuangshuang Lu; Huahui Zhang; Zhanju Liu
Journal:  Exp Ther Med       Date:  2021-12-10       Impact factor: 2.447

Review 5.  Protease-Activated Receptors - Key Regulators of Inflammatory Bowel Diseases Progression.

Authors:  Damian Jacenik; Jakub Fichna; Ewa Małecka-Wojciesko; Anna Mokrowiecka
Journal:  J Inflamm Res       Date:  2021-12-29

Review 6.  Microbiota-Immune Interactions in Ulcerative Colitis and Colitis Associated Cancer and Emerging Microbiota-Based Therapies.

Authors:  Jelena Popov; Valentina Caputi; Nandini Nandeesha; David Avelar Rodriguez; Nikhil Pai
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

7.  Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity.

Authors:  Robert H Mills; Parambir S Dulai; Yoshiki Vázquez-Baeza; Consuelo Sauceda; Noëmie Daniel; Romana R Gerner; Lakshmi E Batachari; Mario Malfavon; Qiyun Zhu; Kelly Weldon; Greg Humphrey; Marvic Carrillo-Terrazas; Lindsay DeRight Goldasich; MacKenzie Bryant; Manuela Raffatellu; Robert A Quinn; Andrew T Gewirtz; Benoit Chassaing; Hiutung Chu; William J Sandborn; Pieter C Dorrestein; Rob Knight; David J Gonzalez
Journal:  Nat Microbiol       Date:  2022-01-27       Impact factor: 30.964

8.  Human Fecal Microbiota Transplantation Reduces the Susceptibility to Dextran Sulfate Sodium-Induced Germ-Free Mouse Colitis.

Authors:  Yapeng Yang; Xiaojiao Zheng; Yuqing Wang; Xiang Tan; Huicong Zou; Shuaifei Feng; Hang Zhang; Zeyue Zhang; Jinhui He; Bota Cui; Xueying Zhang; Zhifeng Wu; Miaomiao Dong; Wei Cheng; Shiyu Tao; Hong Wei
Journal:  Front Immunol       Date:  2022-02-14       Impact factor: 7.561

Review 9.  Microbial-Driven Immunological Memory and Its Potential Role in Microbiome Editing for the Prevention of Colorectal Cancer.

Authors:  Laure Campillo-Gimenez; David Rios-Covian; Jesus Rivera-Nieves; Hiroshi Kiyono; Hiutung Chu; Peter B Ernst
Journal:  Front Cell Infect Microbiol       Date:  2021-11-12       Impact factor: 5.293

10.  Fecal Amino Acid Analysis in Newly Diagnosed Pediatric Inflammatory Bowel Disease: A Multicenter Case-Control Study.

Authors:  Jasmijn Z Jagt; Eduard A Struys; Ibrahim Ayada; Abdellatif Bakkali; Erwin E W Jansen; Jürgen Claesen; Johan E van Limbergen; Marc A Benninga; Nanne K H de Boer; Tim G J de Meij
Journal:  Inflamm Bowel Dis       Date:  2022-05-04       Impact factor: 7.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.